18 June 2001

Cyclacel Limited, the UK-based cancer therapeutics company, announced today the launch of its new website. Interested parties are invited to view the site at www.cyclacel.com where they can find detailed information on the Company, its technology, its research programmes and its commercial collaborations.

Included within the website is information regarding CYC202, Cyclacel's lead drug candidate, which entered Phase I clinical trials in cancer patients earlier this year. CYC202 is a novel cell cycle drug belonging to the Cyclin Dependent Kinase (CDK) inhibitor class. CDK inhibition has been widely recognised as an important new area in the quest for drugs that restore the molecular mechanism of the body's own cancer stopping genes. Commercial activities described include Cyclacel's recent collaboration with AstraZeneca, announced in April this year, to advance Cyclacel's CYC103 programme. Cyclacel and AstraZeneca will be working together to develop small molecule drugs that mimic the body's own anticancer proteins which stop the cell cycle and push cancer cells to commit suicide.

The website also contains up-to-date news releases, business development opportunities and Company contact details.

Notes to Editors:
Cyclacel Limited is a biotechnology company developing novel therapeutics for treating cancer and other serious diseases by employing insights in cell cycle control biology and state-of-the-art rational drug design chemistry. Cyclacel's portfolio includes small molecule CDK inhibitors (CYC200 and CYC400), Pimetic™ small molecules mimicking the function of natural cancer suppressing gene proteins (CYC100), Penetratin®-small molecule complexes (CYC300), and intelligent screening, delivery and targeting systems (Fluorescience®, Penetratin® and SGC™ technologies). The Polgen division is in a world-first effort to validate target biology, develop assays and discover drugs arising from over 100 genomic targets regulating cancer cell division.

Cell Cycle Inhibitors are novel classes of drugs, such as Cyclin Dependent Kinase (CDK) enzyme inhibitors and Cyclin Binding Groove macromolecular substrate inhibitors, that act on the same targets as the protein products of the body's own cancer stopping genes. Tumour suppressor genes, such as p53 and p21, stop cancer cells at cell cycle checkpoints and cause them to die. The goal of cancer treatment with cell cycle drugs is to emulate the behaviour of tumour suppressor genes and cause cancer cells to die by committing suicide in a process called apoptosis.

© 2001 - Cyclacel Limited. Cyclacel®, Fluorescience® and Penetratin® are registered trademarks.